Phenylketonuria:
Optimizing Therapeutic Efficacy

Expanded Reference List


Kaye CI and the Committee on Genetics. Newborn screening fact sheets. *Pediatrics.* 2006;118;e934-e963.


Longo N, Harding CO, Burton BK, et al. A phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of single, subcutaneous doses of rAvPAL-PEG in subjects with phenylketonuria. Presented at European Society of Phenylketonuria and Allied Disorders Treated as Phenylketonuria. Belek, Turkey, June 2009.


